Epigenetic silencing of ZNF154 was associated with multiple cancers and could serve as a biomarker predicting the recurrence of alcohol-associated pancreatic cancer (Yamada et al., 2016; Mishra et al., 2019; Wiesmueller et al., 2019), as well as non-alcohol-associated prostate cancer (Nahar et al., 2018) and bladder cancer (Reinert et al., 2012). Here, ZNF154 is linked to familial pancreatic carcinoma.